SOURCE: SRI International

October 25, 2007 08:30 ET

SRI International Awarded National Cancer Institute Contract to Evaluate Potential Cancer Drugs

MENLO PARK, CA--(Marketwire - October 25, 2007) - SRI International, an independent nonprofit research and development organization, today announced that it has been awarded a $7.9 million contract by the National Cancer Institute (NCI) to conduct analytical chemistry evaluations of anti-cancer drugs and dosage formulations. The new contract, which was awarded to SRI by the NCI's Pharmaceutical Resources Branch as part of their Developmental Therapeutics Program, aims to further the development of promising compounds by providing resources to investigators developing new therapies.

"By conducting in-depth chemical analysis of promising drug candidates, we can help expedite the flow of new anti-cancer discoveries to the clinic," said Jennie Wang, analytical chemistry program director in SRI's Biosciences Division. "Analytical chemistry data can help improve the safety and consistency of drug development at all stages of research."

Fundamental to the drug development process, analytical chemistry helps identify and quantify a drug, specifically determining its identity, strength, quality and stability. This chemical data provides a clear definition of the drug substance or dosage formulation, leading to safer and more effective therapies.

A leading provider of analytical chemistry and cancer research, SRI has supported the NCI's drug development efforts for more than 50 years. SRI also participates in analytical contracts and projects for the National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), the U.S. Army, and biotechnology and pharmaceutical companies, among others.

About SRI's Biosciences Division

SRI International's Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all of the resources necessary to take R&D programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials -- and specializes in cancer, immunology, infectious disease, and neuroscience research. To date, SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.

Contact Information